Drug intelligence / Profile preview

vamikibart

Development stage: Phase 3
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravitreal, Ophthalmic

Overview

Vamikibart is a recombinant fully humanized IgG2 monoclonal antibody that targets interleukin-6 (IL-6). It is engineered specifically for intravitreal (IVT) administration to treat ocular diseases with an inflammatory component. Vamikibart inhibits both cis and trans IL-6 signaling pathways, thereby reducing recruitment of inflammatory cells, restoring blood–retinal barrier integrity, and decreasing vascular leakage and macular edema formation. The Fc region of vamikibart is designed for rapid systemic clearance to minimize systemic adverse effects. Its primary indications under investigation are uveitic macular edema (UME) and diabetic macular edema (DME)[1][2][5].

Other names: vamikibart

Targets

IL-6 (Interleukin 6)

Beyond the preview

Go deeper on vamikibart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vamikibart.

Explore the full profile